Evaluation of Multidrug Resistance and Tem and Shv Broad-Spectrum Beta-Lactamase Genes in Escherichia Coli Obtained From Patients With Urinary Tract Infections in Alborz Province, Iran



Mm Soltan Dalal Mohammad MEHDI ; Sz Mirbagheri Seyedeh Z ; S Vahedi SAEED ; Mr Mohammadi Mohammad REZA ; Hma Mirzaei Hedroosha Molla AGHA
Source: Journal of Advances in Medical and Biomedical Research Published:2024

Abstract

Background & Objective: Investigating multidrug resistance and TEM and SHV broad-spectrum beta-lactamase genes in Escherichia coli bacteria isolated from patients with urinary tract infections is very useful to improve the treatment of infection and prevent the failure of treatment of urinary tract infections.The aim of this study was to investigate multidrug resistance and TEM and SHV broad-spectrum beta-lactamase genes in Escherichia coli bacteria isolated from patients with urinary tract infections. Materials & Methods: In this study, 188 strains of Escherichia coli, which cause urinary tract infections in Alborz province, were studied. Urine samples were cultured on EMB and Blood Agar media. Differential tests were performed for final identification. ESBL-producing strains were identified, PCR was performed to survey the abundance of ESBL-producing genes. Results: Based on the results of the disk diffusion and Double-disk synergy testS, 82 (43.6%) strains were determined as the final producer of ESBL. out of these isolates, the frequency of SHV, TEM, and CTX genes measured 64.3%, 55.9%, and 21.4%, respectively. These results showed that 12 (14.28%) of Escherichia coli isolated have all genes, 26 (30.95%) had 2 genes and 36 (42.85%) had one gene. Conclusion: According to the results, it was found that imipenem with the lowest resistance is the best drug in the treatment, and carbapenems are the best drug for treating diseases caused by Escherichia coli. The results of the current study may be useful in replacing ESBL enzyme resistance screening with more modern sensitivity measurement methods such as MIC and Etest. © 2024 Elsevier B.V., All rights reserved.